Compare CTLP & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTLP | LXEO |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | | |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 798.9M | 731.3M |
| IPO Year | N/A | N/A |
| Metric | CTLP | LXEO |
|---|---|---|
| Price | $9.98 | $6.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | N/A | ★ $18.60 |
| AVG Volume (30 Days) | ★ 1.6M | 841.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.11 | N/A |
| Revenue Next Year | $14.37 | N/A |
| P/E Ratio | $13.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.01 | $1.45 |
| 52 Week High | $11.36 | $10.99 |
| Indicator | CTLP | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 19.74 | 30.48 |
| Support Level | $10.37 | $6.73 |
| Resistance Level | $10.74 | $7.31 |
| Average True Range (ATR) | 0.17 | 0.48 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 1.11 | 13.60 |
Cantaloupe Inc is a technology leader powering self-service commerce by offering one integrated solution for payments processing, logistics, and back-office management. The group offers a comprehensive suite of solutions, including micro-payment processing, self-checkout kiosks, mobile ordering, connected point-of-sale (POS) systems, and enterprise cloud software. Its product and services portfolio consists of Card Readers, Self-Service Kiosks, Smart Coolers, Seed Pick Easy, Cantaloupe Go, Cheq, Smart Lock Connect, and Vine Digital Studio. The company derives revenue streams from subscriptions, transaction processing, and equipment sales.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.